Lisa A Carey

Lisa A Carey

UNVERIFIED PROFILE

Are you Lisa A Carey?   Register this Author

Register author
Lisa A Carey

Lisa A Carey

Publications by authors named "Lisa A Carey"

Are you Lisa A Carey?   Register this Author

100Publications

3785Reads

24Profile Views

Race and delays in breast cancer treatment across the care continuum in the Carolina Breast Cancer Study.

Cancer 2019 Nov 9;125(22):3985-3992. Epub 2019 Aug 9.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819218PMC
November 2019

Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study.

PLoS One 2019 25;14(1):e0211488. Epub 2019 Jan 25.

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211488PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347264PMC
October 2019

Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

J Clin Oncol 2019 Sep 3;37(25):2189-2192. Epub 2019 Jun 3.

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.01159DOI Listing
September 2019

Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.

Nat Commun 2019 Sep 13;10(1):4192. Epub 2019 Sep 13.

UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-12222-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744422PMC
September 2019

An assessment of prognostic immunity markers in breast cancer.

NPJ Breast Cancer 2018 29;4:35. Epub 2018 Oct 29.

5Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41523-018-0088-0
Publisher Site
http://dx.doi.org/10.1038/s41523-018-0088-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206135PMC
October 2018

Financial Impact of Breast Cancer in Black Versus White Women.

J Clin Oncol 2018 06 18;36(17):1695-1701. Epub 2018 Apr 18.

Stephanie B. Wheeler, Jennifer C. Spencer, Lisa A. Carey, Andrew F. Olshan, and Katherine E. Reeder-Hayes, University of North Carolina at Chapel Hill, Chapel Hill, NC; and Laura C. Pinheiro, Weill Cornell Medicine, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993169PMC
June 2018

Influence of provider factors and race on uptake of breast cancer gene expression profiling.

Cancer 2018 04 16;124(8):1743-1751. Epub 2018 Jan 16.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31222DOI Listing
April 2018

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.

J Natl Cancer Inst 2018 02;110(2)

Department of Epidemiology, Lineberger Comprehensive Cancer Center; Department of Pathology and Lab Medicine, Department of Nutrition (EHA), and Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC; Dana Farber Cancer Institute, Harvard University, Boston, MA; Center for Clinical Cancer Genetics, Global Health Department of Medicine, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059138PMC
February 2018

Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.

Clin Breast Cancer 2018 02 9;18(1):29-37. Epub 2017 Aug 9.

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2017.07.017DOI Listing
February 2018

Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

Breast Cancer Res Treat 2018 01 14;167(1):235-248. Epub 2017 Sep 14.

Division of Hematology/Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4501-4DOI Listing
January 2018

Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment.

Pharmacogenet Genomics 2017 11;27(11):402-409

aDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan bUNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina cDeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida dDepartment of Clinical Pharmacology, Indiana University, Indianapolis, Indiana eBon Secours Cancer Institute, Richmond, Virginia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659294PMC
November 2017

Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer.

J Clin Oncol 2017 Oct 20;35(29):3298-3305. Epub 2017 Jul 20.

Katherine E. Reeder-Hayes, Anne Marie Meyer, Sharon Peacock Hinton, Ke Meng, Lisa A. Carey, and Stacie B. Dusetzina, University of North Carolina at Chapel Hill (UNC) Lineberger Comprehensive Cancer Center; Katherine E. Reeder-Hayes and Ke Meng, UNC Lineberger Integrated Cancer Information and Surveillance System; Katherine E. Reeder-Hayes and Lisa A. Carey, UNC School of Medicine; and Stacie B. Dusetzina, Cecil G. Sheps Center for Health Services Research, UNC Eshelman School of Pharmacy, and UNC Gillings School of Global Public Health, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.4345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652869PMC
October 2017

Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer.

JNCI Cancer Spectr 2017 Sep 23;1(1):pkx004. Epub 2017 Sep 23.

School of Medicine (JJM, BRB), Lineberger Comprehensive Cancer Center (AMD, JLL, LAC, TMZ, ELJ, LBM, RCC), Biostatistics Core Facility (AMD), Department of Epidemiology, Gillings School of Global Public Health (JLL), Division of Hematology-Oncology (LAC), Department of Radiation Oncology (TMZ, ELJ, LBM, RCC), Sheps Center for Health Services Research (RCC), University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pkx004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649828PMC
September 2017

De-escalating and escalating systemic therapy in triple negative breast cancer.

Authors:
Lisa A Carey

Breast 2017 Aug 8;34 Suppl 1:S112-S115. Epub 2017 Jul 8.

University of North Carolina, North Carolina, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776173051
Publisher Site
http://dx.doi.org/10.1016/j.breast.2017.06.041DOI Listing
August 2017

Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?

Clin Cancer Res 2017 Jun;23(11):2611-2616

Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-2633DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512575PMC
June 2017

Weight changes in postmenopausal breast cancer survivors over 2 years of endocrine therapy: a retrospective chart review.

Breast Cancer Res Treat 2017 04 2;162(2):375-388. Epub 2017 Feb 2.

Oncology Institute, Rambam Health Care Campus, Haifa, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-017-4106-yDOI Listing
April 2017

Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.

J Clin Oncol 2017 Mar 21;35(7):751-758. Epub 2016 Nov 21.

Kala Visvanathan, Johns Hopkins University School of Medicine and Bloomberg School of Public Health; MaryJo S. Fackler, Zhe Zhang, Zoila A. Lopez-Bujanda, Stacie C. Jeter, Lori J. Sokoll, Leslie M. Cope, Christopher B. Umbricht, David M. Euhus, Saraswati Sukumar, and Antonio C. Wolff, Johns Hopkins University School of Medicine, Baltimore, MD; Elizabeth Garrett-Mayer, Medical University of South Carolina, Charleston, SC; Andres Forero, University of Alabama at Birmingham, Birmingham, AL; Anna M. Storniolo, Indiana University, Bloomington, IN; Rita Nanda, University of Chicago, Chicago, IL; Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; and James N. Ingle, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.2080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455421PMC
March 2017

Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

J Clin Oncol 2017 Feb 19;35(4):421-431. Epub 2016 Dec 19.

Rachel A. Freedman, Eric P. Winer, and Ann H. Partridge, Dana-Farber Cancer Institute, Boston, MA; Jared C. Foster, Drew K. Seisler, Jacqueline M. Lafky, and Aminah Jatoi, Mayo Clinic; Jared C. Foster and Drew K. Seisler, Mayo Cancer Center, Rochester, MN; Hyman B. Muss and Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Harvey J. Cohen, Constance Cirrincione, and Gretchen Kimmick, Duke University, Durham, NC; Jeanne Mandelblatt, Georgetown University, Washington, DC; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; Alvaro Moreno-Aspitia, Mayo Clinic, Jacksonville, FL; and Arti Hurria, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4182DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455700PMC
February 2017

Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.

J Am Coll Surg 2016 11;223(5):717-728.e4

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC; Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamcollsurg.2016.08.541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059614PMC
November 2016

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

J Clin Oncol 2016 08 2;34(22):2602-9. Epub 2016 May 2.

Maura N. Dickler, Mary Ellen Moynahan, Diana E. Lake, and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; William T. Barry, Dana-Farber Cancer Institute; Eric P. Winer, Dana-Farber/Partners Cancer Care, Boston, MA; Constance T. Cirrincione, Duke University, Durham, NC; Matthew J. Ellis, Baylor College of Medicine; Debasish Tripathy, The University of Texas MD Anderson Cancer Center, Houston, TX; Federico Innocenti and Lisa A. Carey, University of North Carolina at Chapel Hill, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte; Hope S. Rugo, University of California at San Francisco, San Francisco, CA; Olwen Hahn, Alliance for Clinical Trials in Oncology, Chicago, IL; and Bryan P. Schneider, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690PMC
August 2016

I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment.

N Engl J Med 2016 Jul;375(1):83-4

From the Division of Hematology-Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill (L.A.C.); and the Breast Oncology Program, Dana-Farber Cancer Institute, Boston (E.P.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1603691DOI Listing
July 2016

Another Breast Cancer Entity Confirmed: Genomics of Invasive Lobular Breast Cancer.

J Clin Oncol 2016 06 28;34(16):1838-9. Epub 2016 Mar 28.

University of North Carolina at Chapel Hill, Chapel Hill, NC

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.3872DOI Listing
June 2016

Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.

J Clin Oncol 2016 06 11;34(17):2003-9. Epub 2016 Apr 11.

All authors: University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.8716DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966516PMC
June 2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Breast Cancer Screening in Low- and Middle-Income Countries: A Perspective From Malawi.

J Glob Oncol 2016 Feb 23;2(1):4-8. Epub 2015 Dec 23.

, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; , , , and , UNC-Project Malawi; , Malawi Ministry of Health; and , Kamuzu Central Hospital, Lilongwe; and , University of Malawi College of Medicine, Blantyre, Malawi; , Gillings School of Global Public Health; , , and , Lineberger Comprehensive Cancer Center; and , Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2015.000430DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497737PMC
February 2016

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.

J Clin Oncol 2016 Jan 23;34(2):130-8. Epub 2015 Nov 23.

Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Katherine E. Reeder-Hayes, Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler, University of North Carolina at Chapel Hill, Chapel Hill; Morris Weinberger, Durham Veterans Affairs Medical Center for Health Services Research; and Michaela A. Dinan, Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.63.2489
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.2489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872005PMC
January 2016

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience.

Oncologist 2016 Jan 9;21(1):16-20. Epub 2015 Dec 9.

University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA Department of Radiation Oncology, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA Department of Neurosurgery, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709216PMC
January 2016

Neoadjuvant clinical trial designs: Challenges of the genomic era.

Authors:
Lisa A Carey

Breast 2015 Nov 1;24 Suppl 2:S88-90. Epub 2015 Aug 1.

University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, 170 Manning Drive, CB7305, Chapel Hill, NC 27599-7305, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776150015
Publisher Site
http://dx.doi.org/10.1016/j.breast.2015.07.021DOI Listing
November 2015

CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.

Authors:
Lisa A Carey

Clin Cancer Res 2015 Sep;21(18):4027-9

The University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-3124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573539PMC
September 2015

Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.

Breast Cancer Res Treat 2015 Aug 28;153(1):191-200. Epub 2015 Jul 28.

Health Policy Management, Gillings School of Global Public Health, University of North Carolina, 135 Dauer Drive, McGavran Greenberg Hall, CB #7411, Chapel Hill, NC, 27599-7411, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-015-3518
Web Search
http://link.springer.com/10.1007/s10549-015-3518-9
Publisher Site
http://dx.doi.org/10.1007/s10549-015-3518-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562432PMC
August 2015

The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.

J Biopharm Stat 2015 ;25(1):66-88

a Department of Biostatistics and Computational Biology , Dana-Farber Cancer Institute , Boston , Massachusetts , USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.1080/10543406.2014.919
Publisher Site
http://dx.doi.org/10.1080/10543406.2014.919933DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459132PMC
July 2015

Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

J Clin Oncol 2015 Jul 8;33(21):2361-9. Epub 2015 Jun 8.

Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Erica L. Mayer and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Alvaro Moreno-Aspitia and Edith A. Perez, Mayo Clinic, Jacksonville, FL; Alan P. Lyss, Heartland Cancer Research Community Clinical Oncology Program; Michael Naughton, Washington University School of Medicine, St Louis, MO; Constance Cirrincione and Eleanor Leung, Alliance Statistics and Data Center, Duke University, Durham; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Deborah Toppmeyer, Cancer Institute of New Jersey, New Brunswick, NJ; and Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.5298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830PMC
July 2015

Palbociclib--Taking Breast-Cancer Cells Out of Gear.

N Engl J Med 2015 Jul;373(3):273-4

From the Departments of Medicine (L.A.C.) and Genetics (C.M.P.), University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1506680DOI Listing
July 2015

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2015 Jun 6;33(17):1902-9. Epub 2015 Apr 6.

Steven J. Isakoff, Lei He, Darrel R. Borger, Dianne M. Finkelstein, Paula D. Ryan, Paul E. Goss, and Leif W. Ellisen, Massachusetts General Hospital Cancer Center; Steven J. Isakoff, Erica L. Mayer, Lei He, Karen Krag, Steven E. Come, Darrel R. Borger, Dianne M. Finkelstein, Judy E. Garber, Paula D. Ryan, Eric P. Winer, Paul E. Goss, and Leif W. Ellisen, Harvard Medical School; Erica L. Mayer, Judy E. Garber, and Eric P. Winer, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center, Boston; Karen Krag, Massachusetts General Hospital/North Shore Cancer Center, Danvers, MA; Tiffany A. Traina, Memorial Sloan Kettering Cancer Center, New York, NY; Lisa A. Carey, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Hope S. Rugo, University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Minetta C. Liu, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; Vered Stearns, The Johns Hopkins University School of Medicine and The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Kirsten Timms, Myriad Genetics; and Anne-Renee Hartman, Myriad Genetic Laboratories, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.6660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451173PMC
June 2015

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425383PMC
May 2015

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Clin Cancer Res 2015 Mar 18;21(5):1098-105. Epub 2014 Dec 18.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1948DOI Listing
March 2015

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer.

Ann Surg Oncol 2015 Mar 20;22(3):874-82. Epub 2014 Dec 20.

Department of Surgery, University of Michigan Breast Care Center, University of Michigan Health Systems, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1245/s10434-014-4279-0
Publisher Site
http://dx.doi.org/10.1245/s10434-014-4279-0DOI Listing
March 2015

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015 Jan 4;33(1):13-21. Epub 2014 Aug 4.

William M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R. Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268249PMC
January 2015

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

N Engl J Med 2015 Jan;372(2):134-41

From the Departments of Medical Oncology (S.M.T., B.A.O., A.H.P., I.E.K., H.J.B., E.P.W.) and Biostatistics and Computation Biology (W.T.B., H.G.), Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital (B.M.) - both in Boston; Breast Cancer Medicine Service, Department of Medicine, Solid Tumor Division, Memorial Sloan Kettering Cancer Center, and Department of Medicine, Weill Cornell Medical Center, New York (C.T.D., C.A.H.), and Department of Medical Oncology, Hofstra North Shore-LIJ School of Medicine, New Hyde Park (I.S.) - all in New York; Sarah Cannon Cancer Center, Department of Medical Oncology, Nashville (D.A.Y.); Department of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham (P.K.M.), and Department of Medical Oncology, University of North Carolina, Chapel Hill (L.A.C.) - both in North Carolina; Cardinal Bernardin Cancer Center, Department of Medicine, Division of Hematology-Oncology, Loyola University Chicago Stritch School of Medicine, Maywood, IL (K.S.A.); Comprehensive Cancer Center, Department of Medicine, Division of Oncology, University of California, San Francisco, San Francisco (H.S.R.); Department of Medical Oncology, Washington University in St. Louis, St. Louis (M.E.); and Johns Hopkins Kimmel Cancer Center, Department of Oncology, Baltimore (A.C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406281DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313867PMC
January 2015

Age-specific changes in intrinsic breast cancer subtypes: a focus on older women.

Oncologist 2014 Oct 20;19(10):1076-83. Epub 2014 Aug 20.

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200998PMC
October 2014

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2014 Oct 2;32(29):3307-29. Epub 2014 Sep 2.

Ann H. Partridge, Dana-Farber Cancer Institute; Steven E. Come, Beth Israel Deaconess Medical Center; Beverly Moy, Massachusetts General Hospital, Boston, MA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria; Michael A. Danso, Virginia Oncology Associates, Norfolk, VA; Lisa A. Carey, University of North Carolina, Chapel Hill, NC; Nancy E. Davidson, University of Pittsburgh Cancer Institute/University of Pittsburgh Medical Center, Pittsburgh, PA; Angelo Di Leo, Sandro Pitigliani Medical Oncology Unit, Prato, Italy; Julie Gralow, University of Washington/Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, The University of Texas MD Anderson Cancer Center, Houston, TX; Douglas Yee, University of Minnesota/Masonic Cancer Center, Minneapolis, MN; Shelley B. Brundage, Patient Representative, Washington, DC; Maggie Wilcox, Independent Cancer Patients' Voice; and Ian E. Smith, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.56.7479
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.7479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042PMC
October 2014

Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research.

Oncologist 2013 12;18(9):986-93. Epub 2013 Aug 12.

Department of Health Policy and Management, Gillings School of Global Public Health.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0243DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3780646PMC
September 2014

Making sense of dual HER2-targeting in early breast cancer?

J Natl Cancer Inst 2014 Sep 15;106(9). Epub 2014 Sep 15.

Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC (LAC); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (WB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju259DOI Listing
September 2014

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.

J Natl Cancer Inst 2014 Aug 19;106(8). Epub 2014 Aug 19.

: Breast Cancer Unit (AP, BA, MV, JC), Department of Medical Oncology (AP, BA, MV, JC, JT), and Translational Genomics Group (AP, MV), Vall d'Hebron Institute of Oncology Barcelona, Spain; Lineberger Comprehensive Cancer Center (LAC, JSP, CMP), Department of Genetics (CMP), and Department of Pathology and Laboratory Medicine (CMP), University of North Carolina, Chapel Hill, NC; Memorial Sloan-Kettering Cancer Center, New York (JB).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151853PMC
August 2014

Defining success in neoadjuvant breast cancer trials.

Lancet 2014 Jul 14;384(9938):115-6. Epub 2014 Feb 14.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01406736146003
Publisher Site
http://dx.doi.org/10.1016/S0140-6736(14)60034-9DOI Listing
July 2014

How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.

J Clin Oncol 2014 Jul 2;32(20):2122-4. Epub 2014 Jun 2.

University of North Carolina-Chapel Hill, Chapel Hill, NC

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.7249DOI Listing
July 2014

Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.

Clin Cancer Res 2014 Jul 10;20(14):3818-29. Epub 2014 Jun 10.

Authors' Affiliations: Lineberger Comprehensive Cancer Center; Medicine; Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102637PMC
July 2014

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy.

Breast Cancer Res Treat 2014 May 6;145(1):245-54. Epub 2014 Apr 6.

Department of Clinical, Social, and Administrative Sciences, University of Michigan College of Pharmacy, 428 Church St, Ann Arbor, MI, 48109, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-014-2910-1
Publisher Site
http://dx.doi.org/10.1007/s10549-014-2910-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256153PMC
May 2014

Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

J Natl Cancer Inst 2014 Apr 28;106(4):dju057. Epub 2014 Mar 28.

Affiliations of authors: Lineberger Comprehensive Cancer Center (HKS, AMD, JK, CT, JS, JGI, LAC, AD, B-BG, SA, NES, HBM), Department of Medicine (HKS, TAJ, GW, LAC, NES, HBM), Department of Genetics (JK, CT, NES), and Department of Biostatistics (JGI), University of North Carolina, Chapel Hill, NC; Department of Medicine, University of Virginia, Charlottesville, VA (PD); Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, CA (AH); Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany (KK, KLR).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982894PMC
April 2014

Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.

Cancer Res 2014 Apr;74(8):2160-70

Authors' Affiliations: Departments of Oncology, Surgery, and Surgical Pathology, Johns Hopkins University School of Medicine; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore Maryland; Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York; Departments of Oncology and Surgery, Mayo Clinic, Rochester, Minnesota; Department of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-3392DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327879PMC
April 2014

Understanding how breast cancer patients use risk information from genomic tests.

J Behav Med 2013 Dec 10;36(6):567-73. Epub 2012 Aug 10.

Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, 325 Rosenau Hall, CB 7440, Chapel Hill, NC, 27599-7440, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10865-012-9449-6
Publisher Site
http://dx.doi.org/10.1007/s10865-012-9449-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535460PMC
December 2013

Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation.

Exp Mol Pathol 2013 Dec 14;95(3):276-87. Epub 2013 Sep 14.

Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA; UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC 27599 USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2013.09.001DOI Listing
December 2013

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Clin Cancer Res 2013 Oct 21;19(19):5505-12. Epub 2013 Aug 21.

Authors' Affiliations: Breast Cancer Medicine Service, Departments of Pathology, Biostatistics, and Radiology, Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Rochester, Minnesota; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia; University of North Carolina at Chapel Hill, Chapel Hill; Duke University Medical Center, Durham, North Carolina; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California; University of Alabama at Birmingham, Birmingham, Alabama; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643PMC
October 2013

The management of early-stage and metastatic triple-negative breast cancer: a review.

Hematol Oncol Clin North Am 2013 Aug 18;27(4):737-49, viii. Epub 2013 Jun 18.

Division of Hematology-Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Drive, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.05.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737488PMC
August 2013

Engaging in health behaviors to lower risk for breast cancer recurrence.

PLoS One 2013 11;8(1):e53607. Epub 2013 Jan 11.

Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053607PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543271PMC
July 2013

Improving endocrine therapy for breast cancer: it's not that simple.

J Clin Oncol 2013 Jan 10;31(2):171-3. Epub 2012 Dec 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.2655DOI Listing
January 2013

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.

Breast Cancer Res Treat 2012 Jul 18;134(1):401-10. Epub 2012 Apr 18.

UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, 120 Mason Farm Road, CB 7361, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2054-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727245PMC
July 2012

Neoadjuvant trials of human epidermal growth factor receptor 2 targeting: how many drugs do we need?

Authors:
Lisa A Carey

J Clin Oncol 2012 Jun 9;30(16):1909-11. Epub 2012 Apr 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.40.9334DOI Listing
June 2012

Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients.

Breast Cancer Res 2012 Mar 19;14(2):R51. Epub 2012 Mar 19.

Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr3152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446385PMC
March 2012